Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

LIA in Hip Arthroscopy Patients: An Extra-Capsular Approach

ID
Name
90371
Description
The investigator's are conducting a randomized, blinded study to determine if the extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine can improve the postoperative pain management of hip arthroscopy patients. Participants will be randomly assigned to the LIA group or non-LIA group prior to surgery. Participants, anesthesiologists and PACU nurses will be blinded to group assignment, however the surgeon administering the LIA will be unblinded.
Trial arms
Trial start
2016-06-01
Estimated PCD
2020-03-01
Trial end
2020-03-01
Status
Completed
Phase
Early phase I
Treatment
20ml 0.25% bupivacaine-epinephrine
Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
Arms:
Treatment
Other names:
Marcaine, Sensorcaine
Size
74
Primary endpoint
PACU pain scores
1-day
Eligibility criteria
Inclusion Criteria: * Adult (\>18 years) patients who have elected for hip arthroscopy surgery. Exclusion Criteria: * Patients who are undergoing bilateral hip arthroscopy in a single surgery.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Participants, anesthesiologists and PACU nurses will be blinded to group assignment, however the surgeon administering the LIA will be unblinded.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 74, 'type': 'ACTUAL'}}
Updated at
2023-05-10

1 organization

1 product

1 indication

Organization
University of Utah
Product
Bupivacaine-Epinephrine
Indication
Pain